loading
Schlusskurs vom Vortag:
$19.84
Offen:
$19.62
24-Stunden-Volumen:
923.77K
Relative Volume:
1.12
Marktkapitalisierung:
$1.31B
Einnahmen:
$9.98M
Nettoeinkommen (Verlust:
$-154.08M
KGV:
-7.6667
EPS:
-2.58
Netto-Cashflow:
$-159.66M
1W Leistung:
-2.80%
1M Leistung:
-5.49%
6M Leistung:
-27.92%
1J Leistung:
-41.17%
1-Tages-Spanne:
Value
$18.80
$19.86
1-Wochen-Bereich:
Value
$18.55
$20.67
52-Wochen-Spanne:
Value
$14.40
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Firmenname
Celldex Therapeutics Inc
Name
Telefon
908-200-7500
Name
Adresse
53 FRONTAGE ROAD, HAMPTON
Name
Mitarbeiter
186
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
CLDX's Discussions on Twitter

Vergleichen Sie CLDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CLDX
Celldex Therapeutics Inc
19.78 1.35B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Eingeleitet Canaccord Genuity Buy
2025-03-20 Eingeleitet Morgan Stanley Overweight
2025-02-13 Eingeleitet UBS Buy
2024-10-07 Eingeleitet Citigroup Buy
2024-09-30 Eingeleitet Goldman Neutral
2024-09-27 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-18 Eingeleitet Stifel Buy
2024-06-11 Eingeleitet Wolfe Research Outperform
2023-12-20 Eingeleitet TD Cowen Outperform
2023-11-10 Hochstufung Wells Fargo Underweight → Equal Weight
2023-08-22 Eingeleitet Wells Fargo Underweight
2021-09-17 Eingeleitet Jefferies Buy
2021-09-10 Eingeleitet SVB Leerink Outperform
2021-07-22 Eingeleitet Guggenheim Buy
2020-02-21 Eingeleitet Cantor Fitzgerald Overweight
2017-08-01 Fortgesetzt H.C. Wainwright Buy
2016-11-07 Eingeleitet Aegis Capital Buy
2016-03-08 Herabstufung Jefferies Buy → Hold
2016-03-07 Herabstufung Guggenheim Buy → Neutral
2016-03-07 Herabstufung Leerink Partners Outperform → Mkt Perform
2016-03-07 Herabstufung Wedbush Outperform → Neutral
2016-03-01 Eingeleitet H.C. Wainwright Buy
2015-08-11 Bestätigt Brean Capital Buy
2015-08-11 Bestätigt Oppenheimer Outperform
2015-08-11 Bestätigt ROTH Capital Buy
2015-06-02 Bestätigt WBB Securities Strong Buy
2014-11-17 Bestätigt ROTH Capital Buy
2014-03-04 Bestätigt Oppenheimer Outperform
2013-07-08 Bestätigt Cantor Fitzgerald Buy
2013-03-08 Bestätigt Cantor Fitzgerald Buy
2013-02-26 Bestätigt Oppenheimer Outperform
2013-01-10 Bestätigt Cantor Fitzgerald Buy
2012-10-02 Bestätigt Oppenheimer Outperform
2012-09-14 Bestätigt Cantor Fitzgerald Buy
Alle ansehen

Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten

pulisher
May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com

May 23, 2025
pulisher
May 22, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com

May 22, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 19, 2025
pulisher
May 13, 2025

Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks

May 13, 2025
pulisher
May 12, 2025

Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World

May 12, 2025
pulisher
May 11, 2025

Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 11, 2025
pulisher
May 11, 2025

Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus

May 11, 2025
pulisher
May 10, 2025

UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus

May 10, 2025
pulisher
May 10, 2025

First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 10, 2025
pulisher
May 09, 2025

Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Repo - GuruFocus

May 09, 2025
pulisher
May 09, 2025

H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Report | CLDX Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Celldex: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 08, 2025

10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Celldex Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Revenue $695K - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - Bluefield Daily Telegraph

May 08, 2025
pulisher
May 07, 2025

Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX

May 07, 2025
pulisher
May 07, 2025

Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada

May 07, 2025
pulisher
May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Interesting CLDX Put And Call Options For June 20th - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - The Manila Times

May 05, 2025
pulisher
May 05, 2025

New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan

May 05, 2025
pulisher
May 03, 2025

Celldex Therapeutics (CLDX) Projected to Post Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
May 02, 2025

Celldex: Q4 Earnings Snapshot - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX

May 02, 2025
pulisher
May 02, 2025

A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News

May 02, 2025
pulisher
May 02, 2025

Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 02, 2025
pulisher
May 02, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 02, 2025
pulisher
May 01, 2025

Celldex Therapeutics Inc’s results are impressive - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com

Apr 30, 2025
pulisher
Apr 29, 2025

Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Analyst Expectations For Celldex Therapeutics's Future - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com

Apr 28, 2025

Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):